Abstract:Protein kinases are frequently dysregulated and/or mutated in cancer and represent essential targets for therapy. Accurate quantification is essential. For breast cancer treatment, the identification and quantification of the protein kinase ERBB2 is critical for therapeutic decisions. While immunohistochemistry (IHC) is the current clinical diagnostic approach, it is only semiquantitative. Mass spectrometry-based proteomics offers quantitative assays that, unlike IHC, can be used to accurately evaluate hundreds of kinases simultaneously. The enrichment of less abundant kinase targets for quantification, along with depletion of interfering proteins, improves sensitivity and thus promotes more effective downstream analyses. Multiple kinase inhibitors were therefore deployed as a capture matrix for kinase inhibitor pulldown (KiP) assays designed to profile the human protein kinome as broadly as possible. Optimized assays were initially evaluated in 16 patient derived xenograft models (PDX) where KiP identified multiple differentially expressed and biologically relevant kinases. From these analyses, an optimized single-shot parallel reaction monitoring (PRM) method was developed to improve quantitative fidelity. The PRM KiP approach was then reapplied to low quantities of proteins typical of yields from core needle biopsies of human cancers. The initial prototype targeting 100 kinases recapitulated intrinsic subtyping of PDX models obtained from comprehensive proteomic and transcriptomic profiling. Luminal and HER2 enriched OCT-frozen patient biopsies subsequently analyzed through KiP-PRM also clustered by subtype. Finally, stable isotope labeled peptide standards were developed to define a prototype clinical method. Data are available via ProteomeXchange with identifiers PXD044655 and PXD046169.

A homogeneous fluorescence polarization assay adaptable for a range of protein serine/threonine and tyrosine kinases

Applications of fluorescent polymer superquenching to high throughput screening assays for protein kinases.

Phosphorylated Protein Chip Combined with Artificial Intelligence Tools for Precise Drug Screening

A homogeneous and nonisotopic assay for phosphatidylinositol 4-kinases

A Fluorescence Polarization-Based High-Throughput Screen to Identify the First Small-Molecule Modulators of the Human Adenylyltransferase HYPE/FICD

Steady State and Time-Dependent Fluorescent Peptide Assays for Protein Kinases

Development of a Universal Phosphorylated Peptide-Binding Protein for Simultaneous Assay of Kinases.

A rapid and cost-effective fluorescence detection in tube (FDIT) method to analyze protein phosphorylation

Multiplex analysis of Src family kinase signaling by microbead suspension arrays

A Time-Resolved Fluorescence Resonance Energy Transfer Assay for High-Throughput Screening of 14-3-3 Protein-Protein Interaction Inhibitors

Facile and Sensitive Method for Protein Kinase A Activity Assay Based on Fluorescent Off-On PolyU-peptide Assembly.

High-Throughput Screening Fluorescence Polarization Assay for Tumor-Specific Hsp90

A mix-and-read fluorescence strategy for the switch-on probing of kinase activity based on an aptameric-peptide/graphene-oxide platform

A Single-step and High-throughput Bioassay for Quantifying Fc-containing Recombinant Proteins Based on Non-classical Calculation of Fluorescence Polarization

A dual-readout F2 assay that combines fluorescence resonance energy transfer and fluorescence polarization for monitoring bimolecular interactions.

Electrochemical detection of kinase by converting homogeneous analysis into heterogeneous assay through avidin-biotin interaction

A fluorescence‐based sensor for calibrated measurement of protein kinase stability in live cells

Multiplexed Quantitative MALDI MS Approach for Assessing Activity and Inhibition of Protein Kinases Based on Postenrichment Dephosphorylation of Phosphopeptides by Metal-Organic Framework-Templated Porous CeO2.

Photocleavable peptide-conjugated magnetic beads for protein kinase assays by MALDI-TOF MS

Automated screening of AURKA activity based on a genetically encoded FRET biosensor using fluorescence lifetime imaging microscopy

Kinase inhibitor pulldown assay (KiP) for clinical proteomics